Background and Aims: Arsenic (iAs) exposure has been associated with several types of cancer (1). However, most studies to date have not yet implicated iAs as a cofactor for breast cancer (BC). BC incidence and mortality are 3-fold higher in Northern Mexico (NM) than in the rest of the country (2). iAs levels in drinking water are a source of concern since they have been above international standards (3). We hypothesized that iAs exposure and individual Arsenic-methylation ability are potential cofactors for BC risk. Methods: We investigated 840 BC incident cases and 973 controls from a population-based case-control study performed in NM. Women were directly interviewed about dietary and reproductive BC covariables. iAs metabolites in urine were determined by HPLC/ICP-MS. Methylation capacity was assessed by calculating the percentage of iAs species and primary [MMA(V)/(As(III)+As(V)] (PMI) and secondary [DMA(V)/MMA(V)] methylation indexes (SMI). Results: The range of total urinary Arsenic was 0.4-303.9 ug/L. Most women (91%) had values above 50 ugAs/L. %MMA(V) was significantly higher in BC cases while %DMA(V) was significantly lower. PMI was positively associated with BC (OR T3vsT1=1.47; 95%CI=1.17-1.84; p for trend=0.001), while SMI was negatively associated (OR T3vsT1=0.54; 95%CI=0.42-0.68; p for trend<0.001).
